Driving Pharmacogenomics Forward: Reflections from the CERSI PGx Workshop

We were proud to participate in the recent CERSI PGx Workshop, hosted by the British Pharmacological Society, which brought together experts from across sectors to accelerate the implementation of pharmacogenomics in healthcare.

Over two days, we explored the progress of work packages focused on guidelines, industry support, training and education, health economics, and patient and public engagement—each delivering tangible outputs that will shape the future of personalised medicine.

Work Package 2 was particularly significant, addressing the needs of industry to continue innovating while solutions are delivered to ensure practical implementation. CERSI PGx and UK-IPN play a vital role here, providing the voice of industry across these work packages and working to remove barriers that could hinder adoption. This collaboration ensures that solutions are co-created to enable pharmacogenomic testing to become part of routine care.

Key sessions featured perspectives from the European Medicines Agency, European Commission, and MHRA, outlining how regulatory bodies are working to create a streamlined environment for pharmacogenomic testing.

A standout moment was Dame Sue Hill's update on the NHS Genomic Medicine Service delivery model within the 10-year health plan, including initiating discussions around funding models to ensure pharmacogenomic tests are integrated into patient pathways.

Beyond the sessions, the workshop provided a valuable opportunity to connect with colleagues across sectors, share ideas, and lay the foundations for collaborative projects aimed at achieving our shared goal: embedding pharmacogenomics into routine care to improve patient outcomes.

As our industry partner, your voice is essential in breaking down barriers and driving innovation. Together, we can accelerate the implementation of pharmacogenomics into patient pathways.